Supportively, knock-down of SIRT6 sensitized non-small cell lung cancer cells to paclitaxel treatment [46], and inhibition of SIRT6 sensitized lymphoma cells to doxorubicin [19]. This evidence concerns the gene SIRT6 and non-small cell lung carcinoma.